Compare Aurora Cannabis Inc (ACB) vs Cronos Group Inc (CRON) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Cronos Group (CRON) trades at $2.75, down 3.85% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue growth of 40% year-over-year to $45.2 million, achieving record net revenue and gross profit. However, net income remains negative at -$9.45 million for 2025, though margins have improved significantly from prior years. Recent news highlights expansion in Canada and Israel, along with a share repurchase program extension.

Outlook is cautiously optimistic with strong revenue growth and market share gains, but profitability challenges and intense cannabis competition pose risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include international expansion and execution on cost controls, while regulatory uncertainty and cash flow volatility remain headwinds for investors.